| Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia (NCT05282108) | Hikma Pharmaceuticals LLC | 2022-07-20 |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies (NCT05362773) | MacroGenics | 2022-07-13 |
| Special Drug Use-results Surveillance of Scemblix Tablets (NCT05421091) | Novartis Pharmaceuticals | 2022-07-04 |
| MargheRITA (Remote Intelligence for Therapeutic Adherence) (NCT05260203) | Advice Pharma Group srl | 2022-06-04 |
| A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia (NCT05304377) | Enliven Therapeutics | 2022-05-22 |
| Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients (NCT05433532) | The First Affiliated Hospital of Soochow University | 2022-05-01 |
| Off-the-shelf NK Cells + SCT for Myeloid Malignancies (NCT05115630) | M.D. Anderson Cancer Center | 2022-04-08 |
| Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia (NCT05130138) | Centre Hospitalier Universitaire de Saint Etienne | 2022-01-27 |
| Italian Treatment Free Remission Registry (NCT04769947) | University of Turin, Italy | 2021-08-09 |
| Dasatinib Down-regulates the Expression of PD-1 and Enhances Killing pH + Leukemia Stem Cells (NCT04991532) | Nanfang Hospital, Southern Medical University | 2021-06-20 |
| KRT-232 and TKI Study in Chronic Myeloid Leukemia (NCT04835584) | Kartos Therapeutics, Inc. | 2021-05-07 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment (NCT04028479) | Taproot Health | 2021-05-05 |
| French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients (NCT05619978) | Novartis Pharmaceuticals | 2021-05-03 |
| Innate T Cells and TKI Discontinuation (NCT04645706) | Poitiers University Hospital | 2021-04-20 |
| TIGIT in Patients With Chronic Myeloid Leukemia (NCT04818619) | Assiut University | 2021-04-01 |
| Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications (NCT04595851) | University of Michigan Rogel Cancer Center | 2021-03-26 |
| Study Conducted Among Patients With CML (NCT05476562) | Novartis Pharmaceuticals | 2021-03-08 |
| Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies (NCT04943757) | St. Petersburg State Pavlov Medical University | 2021-01-21 |
| Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (NCT04626024) | Baylor College of Medicine | 2020-12-22 |
| Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation (NCT05611216) | Novartis Pharmaceuticals | 2020-12-01 |
| Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation (NCT04621851) | University of Milano Bicocca | 2020-09-30 |
| A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors (NCT04605211) | University of California, San Francisco | 2020-09-18 |
| The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation (NCT04233346) | Otsuka Beijing Research Institute | 2020-07-09 |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation (NCT04464889) | Medigene AG | 2020-07-02 |
| CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML (NCT04151706) | Robert Lowsky | 2020-02-27 |
| Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide (NCT03533816) | University of Kansas Medical Center | 2020-01-31 |
| A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) (NCT04578847) | National Research Center for Hematology, Russia | 2020-01-15 |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL (NCT04260022) | Ascentage Pharma Group Inc. | 2020-01-09 |
| Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP (NCT04155411) | Shenzhen Second People's Hospital | 2019-12-01 |
| Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (NCT04013685) | Orca Biosystems, Inc. | 2019-11-21 |
| Frontline Asciminib Combination in Chronic Phase CML (NCT03906292) | University of Jena | 2019-08-19 |
| Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular Response (NCT04104035) | Ankara University | 2019-08-13 |
| Effects of a Digital Patient Platform (CMyLife) for Patients With Chronic Myeloid Leukemia (CML) on Information Provision, Patient Empowerment, Medication Compliance, Guideline Adherence and Quality of Life (NCT04595955) | Radboud University Medical Center | 2019-07-01 |
| Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients (NCT03885830) | UNC Lineberger Comprehensive Cancer Center | 2019-06-20 |
| Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia (NCT04043676) | Fundación Teófilo Hernando, Spain | 2019-04-30 |
| Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors. (NCT03996096) | University Hospital, Caen | 2019-04-23 |
| Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis (NCT03831776) | St. Olavs Hospital | 2019-03-25 |
| A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia (NCT03874858) | Novartis Pharmaceuticals | 2019-03-22 |
| Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia (NCT03348033) | Hospital de Clinicas de Porto Alegre | 2019-03-01 |
| Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia (NCT03455517) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2018-10-31 |
| Selumetinib and Azacitidine in High Risk Chronic Blood Cancers (NCT03326310) | University of Chicago | 2018-09-04 |
| IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT (NCT03696537) | Naoyuki G. Saito, M.D., Ph.D. | 2018-08-29 |
| Iclusig PMS in CML or Ph+ALL Patients (NCT03709017) | Korea Otsuka Pharmaceutical Co., Ltd. | 2018-08-07 |
| Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 (NCT02890758) | Brenda Cooper, MD | 2018-05-22 |
| The Hong Kong CML Registry (NCT03625583) | The University of Hong Kong | 2018-04-01 |
| Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatment (NCT05387330) | Tanta University | 2018-04-01 |
| Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression (NCT03480360) | Dartmouth-Hitchcock Medical Center | 2018-03-28 |
| CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies (NCT03795779) | iCell Gene Therapeutics | 2018-03-01 |
| CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies (NCT04156256) | iCell Gene Therapeutics | 2018-03-01 |
| Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®) (NCT04048564) | Incyte BioSciences France | 2018-02-23 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant (NCT03326921) | Fred Hutchinson Cancer Center | 2018-02-23 |
| Sleep Assessment in CML (NCT03353558) | HaEmek Medical Center, Israel | 2017-12-01 |
| Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia (NCT03228303) | Assiut University | 2017-12-01 |
| Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (NCT03509896) | Bristol-Myers Squibb | 2017-11-30 |
| Effect of Pharmacogenetics on Imatinib Plasma Level and Response (NCT03262974) | Assiut University | 2017-10-29 |
| Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia (NCT03075969) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2017-08-03 |
| The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia (NCT03241199) | The University of Hong Kong | 2017-08-01 |
| KISS Study: Kinase Inhibition With Sprycel Start up (NCT03193281) | University of Auckland, New Zealand | 2017-07-17 |
| Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium (NCT03678454) | Incyte Biosciences Benelux | 2017-02-03 |
| Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT (NCT03018223) | H. Lee Moffitt Cancer Center and Research Institute | 2017-01-31 |
| Preparatory Work to Assess Adherence to Oral Chemotherapy (NCT02895542) | Wake Forest University Health Sciences | 2016-12-20 |
| Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Achieving a Complete Molecular Response by Using Probabilistic Markov Approach (NCT03540654) | University Hospital, Bordeaux | 2016-12-07 |
| Bosutinib in Elderly Chronic Myeloid Leukemia (NCT02810990) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2016-11-17 |
| Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia (NCT02709083) | Emory University | 2016-10-01 |
| 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients (NCT02917720) | European LeukemiaNet | 2016-09-01 |
| Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery (NCT02767388) | University of Nebraska | 2016-09-01 |
| Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia (NCT02883036) | Nanfang Hospital, Southern Medical University | 2016-09-01 |
| Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene (NCT02885766) | Fusion Pharma LLC | 2016-07-01 |
| Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line (NCT05734053) | Novartis Pharmaceuticals | 2016-06-28 |
| Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib (NCT02398825) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2016-06-23 |
| Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders (NCT02663648) | Shandong University | 2016-06-01 |
| A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting (NCT04089839) | Bristol-Myers Squibb | 2016-04-21 |
| Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. (NCT02546674) | Novartis Pharmaceuticals | 2016-02-18 |
| Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis (NCT06042660) | Polish Adult Leukemia Group | 2016-02-01 |
| Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies (NCT02556931) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-12-01 |
| Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML) (NCT02842320) | Centre Hospitalier Universitaire de Besancon | 2015-10-14 |
| Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy (NCT02487069) | Nanfang Hospital, Southern Medical University | 2015-06-01 |
| Radotinib as 3rd or Later Line Therapy in CP-CML (NCT02422719) | Ulsan University Hospital | 2015-04-01 |
| Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients (NCT02253277) | Novartis Pharmaceuticals | 2015-02-18 |
| Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia (NCT02317159) | Cttq | 2015-02-01 |
| Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy (NCT02353728) | Weill Medical College of Cornell University | 2015-01-01 |
| Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02129582) | Case Comprehensive Cancer Center | 2014-11-05 |
| Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia (NCT02115672) | Sheba Medical Center | 2014-11-01 |
| A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients (NCT02204722) | Dong-A ST Co., Ltd. | 2014-10-13 |
| Treatment-free Remission Accomplished With Dasatinib in Patients With CML (NCT02268370) | University Health Network, Toronto | 2014-10-01 |
| LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients (NCT02164903) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2014-09-11 |
| Occupational Status and Hematological Disease (NCT02057185) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2014-09-08 |
| Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients (NCT02201459) | Hospices Civils de Lyon | 2014-08-01 |
| Allogeneic SCT for CML, TKI Failure After TKI Failure (NCT02172365) | University Health Network, Toronto | 2014-03-01 |
| An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years (NCT02174445) | Prof. Dr. Nikolas von Bubnoff | 2014-03-01 |
| A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia (NCT02011945) | Bristol-Myers Squibb | 2014-02-07 |
| Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions (NCT02103322) | Amneal Pharmaceuticals, LLC | 2014-02-01 |
| Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib (NCT01761890) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2014-01-28 |
| Regional Central Database Recording of Chronic Myeloid Leukemia (NCT02869256) | Institut Bergonié | 2014-01-01 |
| Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination (NCT02007811) | University of Erlangen-Nürnberg Medical School | 2013-11-01 |
| Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity (NCT02016833) | PX Biosolutions | 2013-10-01 |
| RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. (NCT01188889) | University of Michigan Rogel Cancer Center | 2013-09-01 |
| Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008 (NCT01903733) | Pfizer | 2013-08-28 |
| Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors (NCT01752062) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2013-05-02 |
| TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study (NCT01860456) | University of Pisa | 2013-05-01 |